Ryvu Therapeutics S.A. (WSE: RVU)

https://www.ryvu.com

Ryvu Therapeutics is a clinical stage biopharmaceutical company developing novel small molecule therapies that address emerging targets in oncology. Pipeline candidates make use of diverse therapeutic mechanisms driven by emerging knowledge of cancer biology, including small molecules directed at kinase, synthetic lethality, immuno-oncology and cancer metabolism targets. SEL120 is a selective CDK8 kinase inhibitor with potential for the treatment of hematological malignancies and solid tumors currently in clinical development for the treatment of acute myeloid leukemia and myelodysplastic syndrome. SEL24/MEN1703 is a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group in clinical development for the treatment of acute myeloid leukemia. Ryvu is listed on the Warsaw Stock Exchange in Poland (WSE:RVU). *

	Start	2020-04-16 splitoff before
	Predecessor	Selvita S.A. (WSE:SLV)
	Industry	drug discovery
	Industry 2	small-molecule drug
	Person	Przewiezlikowski, Pawel (Selvita 201309 CEO + Co-Founder)

	Region	Kraków
	Country	Poland
	City	n. a. Kraków
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for ï¿½About Sectionï¿½: Galapagos N.V.. (4/16/20). "Press Release: Galapagos and Ryvu Announce Research Collaboration". Mechelen & Krakow.

		Record changed: 2021-03-22